Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity

N J McHugh, J Whyte, G Harvey, U F Haustein

Research output: Contribution to journalArticlepeer-review


OBJECTIVE: To determine the frequency and type of autoantibodies present in patients with systemic sclerosis (SSc) associated with an established environmental toxin.

METHODS: Clinical data and sera were available from 14 men with silica-associated SSc who had developed SSc after at least 2 years of exposure to silica at work. Controls included 27 men with silicosis without SSc. Autoantibodies were measured by immunodiffusion, immunoblotting, and functional inhibition of topoisomerase I (topo I).

RESULTS: Nine of the 14 patients with silica-associated SSc had anti-topo I antibodies. All anti-topo I antibodies in the patients with silica-associated SSc and in 14 anti-topo I-positive patients with idiopathic SSc were directed at an active site of topo I, or at least sterically inhibited its function. One patient with silica-associated SSc had anticentromere antibodies. Unexpectedly, 2 patients with silicosis who had no symptoms of a connective tissue disease had autoantibodies to Ro/SS-A and La/SS-B autoantigens.

CONCLUSION: Anti-topo I antibodies are the predominant autoantibodies present in silica-associated SSc. The generation of anti-topo I antibodies in genetically susceptible individuals may depend partly on the patient's sex and on the site of organ involvement, and may be triggered by silica particles acting as an immune adjuvant.
Original languageEnglish
Pages (from-to)1198-1205
Number of pages8
JournalArthritis & Rheumatism
Issue number8
Publication statusPublished - Aug 1994


Dive into the research topics of 'Anti-topoisomerase I antibodies in silica-associated systemic sclerosis. A model for autoimmunity'. Together they form a unique fingerprint.

Cite this